High throughput viral titering of AAV throughout the production continuum

Live30 webinars are thirty minute presentations designed to update you on the latest innovations, applications and data in a fast yet interactive format.

Process development for viral vector manufacturing relies on accurate titers to inform critical decisions. Digital PCR is the established titer method to support AAV manufacturing, but droplet-based methods have historically been challenged by matrix effects and long time to data. Please join us to learn how the Center for Breakthrough Medicines (CBM) has applied nanoplate-based QIAcuity digital PCR technology to achieve accurate titers from multiplexed assays with challenging samples.

What you will learn:

• How new advances in digital PCR provide more data, across more sample types, faster, and with higher throughput: 
• Critical factors to consider when choosing automated platforms for AAV viral titer determination 
• Strategies to efficiently quantify more targets in the same sample 
• Pushing past common droplet busting matrices to expand testing throughout the AAV process continuum

Kelly Geosits

Associate Scientist at

Kelly Geosits is a Research & Development Associate Scientist at Center for Breakthrough Medicine. Kelly graduated from the University of the Sciences in Philadelphia with a BS in Microbiology in 2014. Her undergraduate research focused on microtubule dynamics in the cytoskeleton. After graduation, she worked on research projects at Hahnemann Hospital through Drexel College of Medicine focusing on paracrine signaling in metastatic pancreatic ductal adenocarcinoma. Kelly had brief sales roles before working at Puresyn, a plasmid DNA manufacturer, where she worked in purification and eventually in quality assurance. She is thrilled to be back in a laboratory research setting focusing on Upstream Process Development for AAV gene therapy.

Watch now

SPEAKERS

Kelly Geosits

Associate Scientist at

You might also like

Development of an automated AAV capsid titer assay on a high-throughput platform

Matthew J.Lotti, John Chappell

3 September

Watch

Accelerating AAV production: optimizing compound identification and process parameters

Keara Sutherland, Jean-Marc Guedon

20 November

Watch

Harnessing flow cytometry for high-throughput screening in immunotherapy development

K Chen, J Riddell, R Cimbro

12 November

Watch

Discover the road to success for viral vector production: strategies, insights, and regulatory considerations

S Shore, A Gilbert, J Bishop

20 June

Watch

Increasing efficiency in AAV-based gene therapy production: platform optimization with multiserotype AAV affinity capture

Nicolas Laroudie, Tiago Albano

27 March

Watch